(Q43696186)
Statements
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (English)
Vincent Ribrag
Jehan Dupuis
Herve Tilly
Franck Morschhauser
Fabrice Laine
Roch Houot
Christiane Copie
Andrea Varga
John Lambert
Laurence Hatteville
Samira Ziti-Ljajic
Anne Caron
Sandrine Payrard
Bertrand Coiffier
16 October 2013